| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Sitagliptin in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control |
Ongoing |
Sitagliptin |
3 |
MK0431-083 |
NGHA-R |
| A Phase III, Multicenter, Double-Blind, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A (A Fixed-Dose Combination Tablet of Sitagliptin and Metformin) in Pediatric Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Therapy (Alone or in Combination With Insulin) |
Completed |
MK-0431A (Sitagliptin / Metformin) |
3 |
MK0431-170 |
NGHA-R |
| A Phase III, Double-Blind, Randomised Study to Assess the Efficacy and Safety of AZD9291 versus a Standard of Care Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer |
Completed |
AZD9291 |
3 |
D5160C00007 |
KFSH&RC-R |
| A Phase III Study of Trastuzumab Deruxtecan (T-DXd) with or without Pertuzumab versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09) |
Ongoing |
Trastuzumab-deruxtecan (Enhertu) |
3 |
D967UC00001 |
King Fahad Specialist Hospital (Dammam) |
| A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) |
Completed |
MEDI4736+Tremelimumab |
3 |
D419AC00003 |
KKUH |
| A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory acute graft vs. host disease after allogenic stem cell transplantation |
Completed |
Ruxolitinib (INC424) (Jakavi) |
3 |
CINC424C2301 |
KFSH&RC-R |
| A phase III randomized open-label multi-center study of ruxolitinib vs. best available therapy in patients with corticosteroid-refractory chronic graft versus host disease after allogenic stem cell transplantation |
Ongoing |
Ruxolitinib (INC424) (Jakavi) |
3 |
CINC424D2301 |
KFSH & RC-R |
| A Phase III Multicenter, Double-Blind, Randomized, Placebo- Controlled Clinical Trial to Evaluate the Safety and Efficacy of MK-0431A XR (a Fixed-Dose Combination Tablet of Sitagliptin and Extended-Release Metformin) in Pediatric Subjects with Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy |
Completed |
SITAGLIPTIN/ METFORMIN XR |
3 |
MK0431A XR-289 |
KKUH |
| "A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Paclitaxel Versus Placebo + Paclitaxel as First-line Treatment for Patients with Histologically Confirmed, Locally Advanced (Inoperable) or Metastatic Triple-Negative Breast Cancer (TNBC)" |
Ongoing |
Capivasertib |
3 |
D3614C00001 |
KFSH-D |
| A phase II, multicenter, open label study of treatment escalation to ACVD (Adriamycin, Cyclophosphamide, Vinblastine and Dacarbazine) and Brentuximab-Vedotin in advanced-stage Hodgkin Lymphoma patients with a positive interim PET scan after 2 ABVD cycles (OPTIMIST study) |
Ongoing |
DOXORUBICIN HYDROCHLORIDE |
2 |
RC16/150 |
NGHA-R |
